Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor

[1]  Sunkyung Lee,et al.  Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor , 2015, Archives of Pharmacal Research.

[2]  I. Gaidarov,et al.  Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential. , 2013, Cellular signalling.

[3]  D. Connolly,et al.  (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans. , 2012, Journal of medicinal chemistry.

[4]  W. Greenlee,et al.  Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. , 2012, ACS medicinal chemistry letters.

[5]  S. Tunaru,et al.  Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. , 2010, The Journal of clinical investigation.

[6]  J. Benovic,et al.  Internalization of the Human Nicotinic Acid Receptor GPR109A Is Regulated by Gi, GRK2, and Arrestin3* , 2010, The Journal of Biological Chemistry.

[7]  M. Forrest,et al.  Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate. , 2010, Journal of medicinal chemistry.

[8]  J. Violin,et al.  beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. , 2009, The Journal of clinical investigation.

[9]  P. D. Boatman,et al.  Nicotinic acid receptor agonists. , 2008, Journal of medicinal chemistry.

[10]  D. Connolly,et al.  Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. , 2008, Journal of clinical lipidology.

[11]  Ning Ren,et al.  Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. , 2008, Bioorganic & medicinal chemistry letters.

[12]  D. Connolly,et al.  Nicotinic Acid Receptor Agonists Differentially Activate Downstream Effectors* , 2007, Journal of Biological Chemistry.

[13]  A. IJzerman,et al.  Nicotinic acid receptor subtypes and their ligands , 2007, Medicinal research reviews.

[14]  D. Connolly,et al.  Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. , 2007, Journal of medicinal chemistry.

[15]  S. Offermanns.  The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. , 2006, Trends in pharmacological sciences.

[16]  Z. Benyó,et al.  GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. , 2005, The Journal of clinical investigation.

[17]  L. Carlson,et al.  Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review , 2005, Journal of internal medicine.

[18]  H. Matsushime,et al.  Molecular identification of nicotinic acid receptor. , 2003, Biochemical and biophysical research communications.

[19]  S. Dowell,et al.  Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid* , 2003, The Journal of Biological Chemistry.

[20]  James Inglese,et al.  Development of an intact cell reporter gene beta-lactamase assay for G protein-coupled receptors for high-throughput screening. , 2003, Analytical biochemistry.

[21]  S. Tunaru,et al.  PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect , 2003, Nature Medicine.

[22]  R. P. Eaton,et al.  Kinetic studies of plasma free fatty acid and triglyceride metabolism in man. , 1969, The Journal of clinical investigation.

[23]  J. Flinn,et al.  Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid. , 1959, A.M.A. archives of internal medicine.

[24]  A. Hoffer,et al.  Influence of nicotinic acid on serum cholesterol in man. , 1955, Archives of biochemistry and biophysics.

[25]  L. Carlson.  NICOTINIC ACID ─ THE BROAD SPECTRUM LIPID DRUG , 2006 .

[26]  M. Guerin,et al.  Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. , 2004, Pharmacology & therapeutics.